Neuropathic pain in cancer.

Area of Science:

• Oncology
• Pain Management
• Neurology

Background:

• Cancer-related neuropathic pain is prevalent, stemming from the disease or treatments like chemotherapy.
• Increasingly effective cancer therapies lead to longer survival but exacerbate treatment side effects, including neuropathy.
• Chemotherapy-induced peripheral neuropathy affects up to 90% of patients receiving neurotoxic agents.

Purpose of the Study:

• To review the challenges and strategies in managing cancer-related neuropathic pain.
• To highlight the importance of comprehensive assessment and oncological management.
• To discuss pharmacotherapeutic options in the context of elderly patients with comorbidities and multiple symptoms.

Main Methods:

• Literature review of cancer-related neuropathic pain management strategies.
• Analysis of current oncological therapies and their impact on neuropathy.
• Discussion of pharmacologic guidelines and their applicability to cancer patients.

Main Results:

• Optimal management hinges on accurate assessment and addressing the root cause of pain.
• A wide array of oncological treatments exist, necessitating careful patient-specific decision-making.
• Limited high-quality clinical trials exist for cancer-related neuropathic pain, complicating treatment selection.

Conclusions:

• Individualized treatment plans are crucial, considering patient age, comorbidities, drug interactions, and coexisting symptoms.
• Opioids are frequently used, alongside standard neuropathic pain agents like anticonvulsants, antidepressants, and topical treatments.
• Avoiding polypharmacy by selecting agents that manage multiple symptoms is a key consideration.